Reports & Insights | Pharma Contract Manufacturing

Interested in seeing who you may meet at Pharma Contract Manufacturing 2025? Download our sample attendee list to see who attended in previous years! Through a 2-day series of workshops, interactive panel sessions, case-studies, and networking opportunities, attendees dived into the latest strategies, developments and insights from leading pharma and...

Present your boss with this customizable letter detailing the reasons why you should attend Pharma Contract Manufacturing 2025 from 26th - 27th March 2025, in Berlin, Germany. Just download the letter template below, adjust as necessary (or edit as needed) and submit! We hope to welcome you there!

Ahead of the Pharma Contract Manufacturing Summit 2023, Pharma IQ spoke exclusively to David Berry, Head of Digital Business Systems - Pharma, CPI about connecting automation to a QP dashboard at the MMIC, to help you discover new opportunities and solutions to your current pharma manufacturing challenges. Fill in the...

The Pharma Contract Manufacturing 2025 conference will focus on fostering long-term, sustainable partnerships in the pharmaceutical manufacturing space. This presentation from 2024 provides key insights into harmonising processes, values, and goals between CMOs and their partners, addressing critical issues such as regulatory compliance, sustainability, and cost management.

The importance of selecting the right CMO/CDMO partnership is critical, as the benefits go beyond significant cost reduction, there is also the potential to improve and develop more strategies for pharmaceutical companies. But only if a mutually collaborative, open and trusting relationship is built. Ahead of the Pharma Contract Manufacturing...

When selecting partners, meeting stringent sustainability criteria along entire pharmaceutical supply chains has far-reaching environmental, economic and reputational benefits. Whilst adding a sustainability criteria to the bidding process is a positive one for driving more responsible operations across the entire pharmaceutical industry, it simultaneously amplifies the complexity of selecting a...

Pharma IQ surveyed over 50 industry professionals, and accompanied by commentary from Ulrich Ruemenapp, Head of Launch Preparation at Bayer, this report will take an in-depth look at the most important components when selecting a CMO, the greatest risks when choosing to outsource and best practises for managing CMO networks.Download...

As pharmaceutical businesses worldwide become more aware of the importance of meeting sustainability goals, it is inevitable that this will become a consideration when selecting a contract manufacturing organisation (CMO) or contract development and manufacturing organisation (CDMO). But it’s important to ensure that meeting sustainability goals when collaborating with external...

Due to the pandemic, the medical needs of populations worldwide are increasing and there is a huge demand for pharmaceutical products, causing CMOs and CDMOs to be increasingly sought after by pharmaceutical companies for their specialist equipment, facilities, labour force and cost-effective production. However, as large pharmaceutical companies start to...

It’s hardly surprising that pharma companies are changing the way they work with external partners, with increasing pressures on quality, cost and scalability determining not only which manufacturers the industry outsources to, but how many partners to take on. With this in mind, Pharma IQ spoke with Simon Hendry, BD...